Only in Titles

Search results for: Mouse Anti-Human CD44v6 Antibodies

paperclip

#20224978   2010/03/12 To Up

Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in vitro.

CD44v6 is a cancer-associated antigen that mainly expresses in a subset of adenocarcinomas. Therefore, in this study, anti-human CD44v6 single-chain variable fragment (scFv) has been selected and characterized because it is the first step of primary importance towards the construction of a novel cancer-targeted agent for cancer diagnosis and therapy. In our study, anti-human CD44v6 scFv was selected from a human phage-displayed scFv library based on its ability to bind in vitro to CD44v6 antigen. Subsequently, immunofluorescent staining and Western blot analyses were performed to measure the binding characteristics of this scFv. In addition, flow cytometric analysis was done to verify its cancer-targeting ability in vitro. And a flow cytometry-based assay was used to determine its equilibrium dissociation constant (K (D)). Finally, one functional anti-CD44v6 scFv was selected and characterized. Nucleotide sequencing verified that it was an incomplete scFv gene but had a variable heavy chain (V(H)) alone. However, anti-CD44v6 scFv demonstrated cell-binding and antigen-binding activities by immunofluorescent staining and Western blot analyses. Furthermore, flow cytometric analysis proved that this scFv specifically targeted CD44v6-expressing cancer cells other than CD44v6 non-expressing normal cells or tumor cells in vitro. The K (D) of this scFv was calculated to be 7.85 +/- 0.93 x 10(-8) M. In summary, the selected human scFv against CD44v6 has specific binding activity and favorable binding affinity despite lacking a variable light chain (V(L)). Moreover, it can effectively and specifically target CD44v6-expressing cancer cells. All these characteristics make anti-CD44v6 scFv a promising agent for cancer detection and anti-cancer therapy.
Yinting Chen, Kaihong Huang, Xuexian Li, Xiangan Lin, Zhaohua Zhu, Ying Wu

2606 related Products with: Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in vitro.

100 μg100 μg100 μg100 μg100 μg500 100 μg100 μg100 μg100 μg

Related Pathways

paperclip

#17277931   2007/02/03 To Up

Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

We tested the suitability of the chimeric monoclonal anti-human CD44 splice version 6 antibody (cMAb U36) for targeting and visualising human anaplastic thyroid carcinoma with PET. We also performed experiments aimed at elucidating the relation between tumour interstitial fluid pressure (TIFP) and the tumour uptake of antibodies.
Marc-André Fortin, Alexei V Salnikov, Marika Nestor, Nils-Erik Heldin, Kristofer Rubin, Hans Lundqvist

1441 related Products with: Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

100ug Lyophilized 100ul 100ul50ul 100ul 100ul 100ul 100ul100ug Lyophilized100ug Lyophilized 100ul100ug Lyophilized

Related Pathways